Joint effect of hypertension and APOE genotype on CSF biomarkers for alzheimer's disease

Journal of Alzheimer's Disease

Volumn 20, Issue 4, 2010, Pages 1083-1090

  Kester, Maartje I ^a   Van Der Flier, Wiesje M ^a   Mandic, Gorana ^b   Blankenstein, Marinus A ^a   Scheltens, Philip ^a   Muller, Majon ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Alzheimer's disease; APOE genotype; CSF biomarkers; hypertension

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PHOSPHORYLATED TAU AT THREONINE 181; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ELECTROENCEPHALOGRAPHY; FEMALE; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SMOKING; CARDIOVASCULAR DISEASES; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COHORT ANALYSIS; COMPLICATION; GENETICS; MIDDLE AGED; PSYCHOLOGY; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RISK FACTORS; TAU PROTEINS;

EID: 77954547365     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091198     Document Type: Article

References (13)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
2. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613.
3. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid {beta}- amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
4. Breteler MM(2000) Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21, 153-160.
5. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. (Pubitemid 126512042)
6. Qiu C, Winblad B, Fratiglioni L (2005) The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4, 487-499.
7. de Leeuw FE, Richard F, de Groot JC, van Duijn CM, Hofman A, Van GJ, Breteler MM (2004) Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 35, 1057-1060. (Pubitemid 38543516)
8. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 21, 57-62.
9. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC, III (1995) Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 131, 162-169.
10. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease (1995) Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 274, 1627-1629.
11. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L (1999) The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282, 40-46.
12. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ (2001) Joint effect of theAPOEgene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke 32, 2882-2889.
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)